Pictet Asset Management
TEVA icon

Pictet Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Pictet Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Sell
544,494
-35,934
-6% -$1.2M 0.02% 548
2026
Q1 		$17.5M Buy
580,428
+23,156
+4% +$745K 0.02% 524
2025
Q4 		$17.4M Buy
557,272
+1,019
+0.2% +$25.1K 0.02% 555
2025
Q3 		$11.2M Sell
556,253
-33,898
-6% -$595K 0.01% 644
2025
Q2 		$9.89M Buy
590,151
+156,917
+36% +$2.53M 0.01% 656
2025
Q1 		$6.65M Sell
433,234
-165,253
-28% -$2.95M 0.01% 750
2024
Q4 		$13.2M Buy
598,487
+52,938
+10% +$963K 0.01% 598
2024
Q3 		$9.83M Buy
545,549
+106,639
+24% +$1.87M 0.01% 657
2024
Q2 		$7.13M Buy
438,910
+32,047
+8% +$494K 0.01% 710
2024
Q1 		$5.74M Buy
406,863
+22,543
+6% +$284K 0.01% 755
2023
Q4 		$4.01M Sell
384,320
-4,802
-1% -$44.8K ﹤0.01% 826
2023
Q3 		$3.97M Buy
+389,122
New +$3.62M ﹤0.01% 816

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Pictet Asset Management's TEVA Position: Q2 2026 in Review

Pictet Asset Management reduced its Teva Pharmaceuticals (TEVA) stake by 6.2% in Q2 2026, selling an estimated $1.2M and leaving 544,494 shares worth $18.4M. The position accounts for 0.02% of the portfolio, ranked #548.

Pictet Asset Management first reported a position in TEVA in Q3 2023 and has held it in 12 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Pictet Asset Management held 544,494 shares of Teva Pharmaceuticals worth $18.4M as of Q2 2026.
  • Pictet Asset Management sold 35,934 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.2M.
  • Teva Pharmaceuticals made up 0.02% of Pictet Asset Management's portfolio in Q2 2026, its #548 holding.
  • Pictet Asset Management first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.